 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Linagliptin | Cas: | 668270-12-0 |
|---|---|---|---|
| Mf: | C25h28n8o2 | Purity: | 99% |
| Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
| High Light: | Linagliptin Active Pharmaceutical Ingredient,668270-12-0 Linagliptin Api Chemical,c25h28n8o2 Linagliptin Api Chemical |
||
Linagliptin Manufacturers Supply High Quality Linagliptin Raw with Best Price CAS 668270-12-0 Linagliptin
| Product name | Linagliptin |
| CAS | 668270-12-0 |
| Appearance | white powder |
| Assay | 99% |
| Storage | Cool and Protect from light |
Product Name:Linagliptin
CAS:668270-12-0
MF:C25H28N8O2
MW:472.54
EINECS:1308068-626-2
Mol File:668270-12-0.mol
Melting point:202 ºC
Boiling point:661.2±65.0 °C(Predicted)
Density 1.39
Description
Linagliptin (TrajentaR, TradjentaTM, TrazentaTM, TrayentaTM) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus.
Treatment of Type 2 diabetesLinagliptin acts to lower blood glucose levels by inhibiting the enzyme DPP-4, thereby preventing the degradation of the incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinsotropic peptide) and attenuating postprandial glucose excursions. By selectively targeting DPP-4, linagliptin potentially causes a more physiologically based control of glucose-dependent postprandial glucose excursions and of fasting blood glucose, both of which are mediated by effects of glucose on insuline and glucagon secretion. An advantage of linagliptin is that since incretin-stimulated release of insuline is glucose dependent, linagliptin is associated with a low incidence of hypoglycaemia. Moreover, DPP-4 inhibitors have a low potential for drug-drug interactions (with the exception of saxagliptin, which is metabolized by cytochrome P450 [CYP] 3A4/5), are generally well tolerated and have minimal or neutral effects on bodyweight.
PharmacokineticsLinagliptin shows modest oral bioavailability, and it is rapidly absorbed. UsesA novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
Usesdipeptidypeptidase inhibitor, antidiabetic
Useshighly potent CD26 inhibitor
UsesLabeled Linagliptin, intended for use as an internal standard for the quantification of Linagliptin by GC- or LC-mass spectrometry.
Contact Person: July
Tel: 25838890
